mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2019-4-116-123mrj-969Research ArticleОБЗОРЫREVIEWSКлиническая значимость ингибиторов Янус-киназ в терапии ревматоидного артрита: достижения и перспективыClinical significance of Janus kinase inhibitors in the therapy of rheumatoid arthritis: achievements and prospectsМазуровВ. И.MazurovV. I.

Вадим Иванович Мазуров

191015, Санкт-Петербург, ул. Кирочная, 41

Vadim Ivanovich Mazurov

41, Kirochnaya Saint Petersburg 191015

maz.nwgmu@yandex.ruБеляеваИ. Б.BelyaevaI. B.

191015, Санкт-Петербург, ул. Кирочная, 41

41, Kirochnaya Saint Petersburg 191015

ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава РоссииРоссияI.I.Mechnikov North-Western State Medical UniversityRussian Federation201923102019134116123Copyright © Мазуров В.И., Беляева И.Б., 20192019Мазуров В.И., Беляева И.Б.Mazurov V.I., Belyaeva I.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/969

В лечении ревматоидного артрита (РА) достигнуты значительные успехи, связанные с применением генно-инженерных биологических препаратов, тем не менее примерно у 36% пациентов не удается получить ответ на терапию или не достичь ожидаемого эффекта. Новым направлением в лечении РА является использование ингибиторов Янус-киназ (JAK) – таргетных синтетических базисных противовоспалительных препаратов (химических молекул с молекулярной массой <1кДа для перорального приема), которые подавляют деятельность внутриклеточных сигнальных систем. Рассмотрены клинические достижения и перспективы, которые открывает применение ингибиторов JAK в лечении РА.

Significant successes in the use of biological agents (BA) have been achieved in the treatment of rheumatoid arthritis (RA); nonetheless, about 36% of patients cannot respond to therapy or achieve the expected effect. A new area in the treatment of RA is the use of Janus kinase (JAK) inhibitors, targeted synthetic disease-modifying anti-rheumatic drugs (chemical molecules with a molecular weight <1 kDa for oral administration) that inhibit the activity of intracellular signaling systems. The authors consider the clinical achievements and prospects, which open the use of JAK inhibitors in the treatment of RA.

ревматоидный артриттаргетная терапияингибиторы Янус-киназтофацитиниббарицитинибгенно-инженерные биологические препаратыrheumatoid arthritistargeted therapyJanus kinase inhibitorstofacitinibbaricitinibbiological agentsПубликация статьи поддержана ООО «Пфайзер Инновации».ReferencesМазуров ВИ, Лила АМ, Зоткин ЕГ, редакторы. Клиническая ревматология. Москва: ФОЛИАНТ; 2005. 515 c.Mazurov VI, Lila AM, Zotkin EG, editors. Klinicheskaya revmatologiya [Clinical rheumatology]. Moscow: FOLIANT; 2005. 515 p.Мазуров ВИ, Трофимов ЕА. Ревматология. Фармакотерапия без ошибок: Руководство для врачей. Москва: Е-ното; 2017. 528 с.Mazurov VI, Trofimov EA. Revmatologiya. Farmakoterapiya bez oshibok: Rukovodstvo dlya vrachei [Rheumatology. Pharmacotherapy without mistakes: A guide for doctors]. Moscow: E-noto; 2017. 528 p.Беляева ИБ, Мазуров ВИ, Трофимова ТН, Трофимов ЕА. Ранний ревматоидный артрит: современные возможности диагностики и лечения. Санкт-Петербург: Медфорум; 2017. 138 с.Belyaeva IB, Mazurov VI, Trofimova TN, Trofimov EA. Rannii revmatoidnyi artrit: sovremennye vozmozhnosti diagnostiki i lecheniya [Early rheumatoid arthritis: modern possibilities of diagnosis and treatment]. Saint-Petersburg: Medforum; 2017. 138 p.Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 464 с.Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2017. 464 p.Насонов ЕЛ. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМА-ПРЕСС; 2013. 552 c.Nasonov EL. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological drugs in the treatment of rheumatoid arthritis]. Moscow: IMA-PRESS; 2013. 552 p.Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016 Jan;68(1):1-25. doi: 10.1002/acr.22783. Epub 2015 Nov 6.Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016 Jan;68(1):1-25. doi: 10.1002/acr.22783. Epub 2015 Nov 6.Charles-Schoeman C, Burmester G, Nash P, et al. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological diseasemodifying anti-rheumatic drugs. Ann Rheum Dis. 2016 Jul;75(7):1293-301. doi: 0.1136/annrheumdis-2014-207178. Epub 2015 Aug 1Charles-Schoeman C, Burmester G, Nash P, et al. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological diseasemodifying anti-rheumatic drugs. Ann Rheum Dis. 2016 Jul;75(7):1293-301. doi: 0.1136/annrheumdis-2014-207178. Epub 2015 Aug 1Giacomelli R, Afeltra A, Alunno A, et al. Guidelines for biomarkersin autoimmune rheumatic diseases – evidence basedanalysis. Autoimmun Rev. 2019 Jan;18(1):93-106. doi: 10.1016/j.autrev.2018.08.003. Epub 2018 Nov 5.Giacomelli R, Afeltra A, Alunno A, et al. Guidelines for biomarkersin autoimmune rheumatic diseases – evidence basedanalysis. Autoimmun Rev. 2019 Jan;18(1):93-106. doi: 10.1016/j.autrev.2018.08.003. Epub 2018 Nov 5.Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford). 2019 Jun 1;58(6):953-962. doi: 10.1093/rheumatology/key339.Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford). 2019 Jun 1;58(6):953-962. doi: 10.1093/rheumatology/key339.Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as atherapeutic strategy for immune and inflammatory diseases. doi: 10.1038/nrd.2017.201Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as atherapeutic strategy for immune and inflammatory diseases. doi: 10.1038/nrd.2017.201Banerjee S, Biehl A, Gadina M, et al. JAK-STAT Signaling as aTarget for Inflammatory and Autoimmune Diseases: Current andFuture Prospects. Drugs. 2017 Apr;77(5):521-546. doi: 10.1007/s40265-017-0701-9.Banerjee S, Biehl A, Gadina M, et al. JAK-STAT Signaling as aTarget for Inflammatory and Autoimmune Diseases: Current andFuture Prospects. Drugs. 2017 Apr;77(5):521-546. doi: 10.1007/s40265-017-0701-9.Gadina M, Johnson C, Schwartz D, et al. Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. J Leukoc Biol. 2018 Sep;104(3): 499-514. doi: 10.1002/JLB.5RI0218-084R. Epub 2018 Jul 12.Gadina M, Johnson C, Schwartz D, et al. Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. J Leukoc Biol. 2018 Sep;104(3): 499-514. doi: 10.1002/JLB.5RI0218-084R. Epub 2018 Jul 12.Насонов ЕЛ, Лила АМ. Ингибиторы янус-киназ при иммуновоспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-пректическая ревматология. 2019;57(1):8-16.Nasonov EL, Lila AM. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects. Nauchno-prekticheskaya revmatologiya = Rheumatology Science and Practice. 2019;57(1): 8-16. (In Russ.). doi: 10.14412/1995-4484-2019-8-16Насонов ЕЛ. Новые подходы к фармакотерапии ревматоидного артрита: тофацитиниб. Научно-практическая ревматология. 2014;52(2):209-21.Nasonov EL. New approaches to pharmacotherapy of rheumatoid arthritis: tofacitinib. Nauchnoprekticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(2):209-21. (In Russ.). doi: 10.14412/1995-4484-2014-209-221Charles-Schoeman C, Burmester G, Nash P, et al. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological diseasemodifying antirheumatic drugs. Ann Rheum Dis. 2016 Jul;75(7):1293-301. doi: 10.1136/annrheumdis-2014-207178. Epub 2015 Aug 14.Charles-Schoeman C, Burmester G, Nash P, et al. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological diseasemodifying antirheumatic drugs. Ann Rheum Dis. 2016 Jul;75(7):1293-301. doi: 10.1136/annrheumdis-2014-207178. Epub 2015 Aug 14.Kunwar S, Collins CE, Constantinescu F. Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematicliterature review and meta-analysis of randomized controlled trials. Clin Rheumatol. 2018 Oct;37(10):2611-2620. doi: 10.1007/s10067-018-4199-7. Epub 2018 Jul 13.Kunwar S, Collins CE, Constantinescu F. Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematicliterature review and meta-analysis of randomized controlled trials. Clin Rheumatol. 2018 Oct;37(10):2611-2620. doi: 10.1007/s10067-018-4199-7. Epub 2018 Jul 13.Shi JG, Chen X, Lee F, et al. The pharmacokinetics, pharmacodynamics,and safety of baricitinib, an oral JAK 1/2 inhibitor, inhealthy volunteers. J Clin Pharmacol. 2014 Dec;54(12):1354-61. doi: 10.1002/jcph.354.Shi JG, Chen X, Lee F, et al. The pharmacokinetics, pharmacodynamics,and safety of baricitinib, an oral JAK 1/2 inhibitor, inhealthy volunteers. J Clin Pharmacol. 2014 Dec;54(12):1354-61. doi: 10.1002/jcph.354.Dhillon S. Tofacitinib: A Review in Rheumatoid Arthritis. Drugs. 2017 Dec;77(18): 1987-2001. doi: 10.1007/s40265-017-0835-9.Dhillon S. Tofacitinib: A Review in Rheumatoid Arthritis. Drugs. 2017 Dec;77(18): 1987-2001. doi: 10.1007/s40265-017-0835-9.Charles-Schoeman C, Burmester G, Nash P, et al. Efficacy andsafety of tofacitinib following inadequate response to conventionalsynthetic or biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2016 Jul;75(7):1293-301. doi: 10.1136/annrheumdis-2014-207178. Epub 2015 Aug 14.Charles-Schoeman C, Burmester G, Nash P, et al. Efficacy andsafety of tofacitinib following inadequate response to conventionalsynthetic or biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2016 Jul;75(7):1293-301. doi: 10.1136/annrheumdis-2014-207178. Epub 2015 Aug 14.Winthrop KL. The emerging safety profile of JAK inhibitors inrheumatic disease. Nat Rev Rheumatol. 2017 Apr;13(4):234-243. doi: 10.1038/nrrheum.2017.23. Epub 2017 Mar 2.Winthrop KL. The emerging safety profile of JAK inhibitors inrheumatic disease. Nat Rev Rheumatol. 2017 Apr;13(4):234-243. doi: 10.1038/nrrheum.2017.23. Epub 2017 Mar 2.Strand V, Kavanaugh A, Kivitz AJ, et al. Long-Term Radiographic and PatientReported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses. Rheumatol Ther. 2018 Dec;5(2):341-353. doi: 10.1007/s40744-018-0113-7. Epub 2018 May 14.Strand V, Kavanaugh A, Kivitz AJ, et al. Long-Term Radiographic and PatientReported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses. Rheumatol Ther. 2018 Dec;5(2):341-353. doi: 10.1007/s40744-018-0113-7. Epub 2018 May 14.Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017 Feb 16;376(7):652-662. doi: 10.1056/NEJMoa1608345.Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017 Feb 16;376(7):652-662. doi: 10.1056/NEJMoa1608345.Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate,and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017 Jul 29;390(10093):457-468. doi: 10.1016/S0140-6736(17)31618-5. Epub 2017 Jun 16.Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate,and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017 Jul 29;390(10093):457-468. doi: 10.1016/S0140-6736(17)31618-5. Epub 2017 Jun 16.Genovese MC, Kremer J, Zamani O, et al. Baricitinib inpatients with refractory rheumatoid arthritis. N Engl J Med. 2016 Mar 31;374(13):1243-52. doi: 10.1056/NEJMoa1507247.Genovese MC, Kremer J, Zamani O, et al. Baricitinib inpatients with refractory rheumatoid arthritis. N Engl J Med. 2016 Mar 31;374(13):1243-52. doi: 10.1056/NEJMoa1507247.Taylor PC. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019 Feb 1; 58(Supplement_1):i17-i26. doi: 10.1093/rheumatology/key225.Taylor PC. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019 Feb 1; 58(Supplement_1):i17-i26. doi: 10.1093/rheumatology/key225.Roman Muller. Jak ingibitors in 2019, synthetic review in 10 poins. Eur J Intern Med. 2019 Aug;66:9-17. doi: 10.1016/j.ejim.2019.05.022. Epub 2019 Jun 6.Roman Muller. Jak ingibitors in 2019, synthetic review in 10 poins. Eur J Intern Med. 2019 Aug;66:9-17. doi: 10.1016/j.ejim.2019.05.022. Epub 2019 Jun 6.Genovese MC, Smolen JS, Weinblatt ME, et al. Efficacyand safety of ABT-494, a selective JAK-1 inhibitor, in aphase IIb study in patients with rheumatoid arthritis and aninadequate response to methotrexate. Arthritis Rheumatol. 2016 Dec;68(12):2857-2866. doi: 10.1002/art.39808.Genovese MC, Smolen JS, Weinblatt ME, et al. Efficacyand safety of ABT-494, a selective JAK-1 inhibitor, in aphase IIb study in patients with rheumatoid arthritis and aninadequate response to methotrexate. Arthritis Rheumatol. 2016 Dec;68(12):2857-2866. doi: 10.1002/art.39808.Westhovens R, Taylor PC, Alten R, et al. Filgotinib(GLPG0634/GS-6034), an oral JAK1 selective inhibitor, iseffective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-findingstudy (DARWIN 1). Ann Rheum Dis. 2017 Jun;76(6):998-1008. doi: 10.1136/annrheumdis-2016-210104. Epub 2016 Dec 19.Westhovens R, Taylor PC, Alten R, et al. Filgotinib(GLPG0634/GS-6034), an oral JAK1 selective inhibitor, iseffective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-findingstudy (DARWIN 1). Ann Rheum Dis. 2017 Jun;76(6):998-1008. doi: 10.1136/annrheumdis-2016-210104. Epub 2016 Dec 19.Genovese MC, Greenwald M, Codding C, et al. Peficitinib,a JAK inhibitor, in combination with limited conventionalsynthetic disease-modifying antirheumatic drugs in thetreatment of moderate-to-severe rheumatoid arthritis. Arthritis Rheumatol. 2017 May;69(5):932-942. doi: 10.1002/art.40054.Genovese MC, Greenwald M, Codding C, et al. Peficitinib,a JAK inhibitor, in combination with limited conventionalsynthetic disease-modifying antirheumatic drugs in thetreatment of moderate-to-severe rheumatoid arthritis. Arthritis Rheumatol. 2017 May;69(5):932-942. doi: 10.1002/art.40054.Fleischmann RM, Damjanov NS, Kivitz AJ, et al. A randomized, double-blind, placebo-controlled, twelve-week,dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with activerheumatoid arthritis. Arthritis Rheumatol. 2015 Feb;67(2):334-43. doi: 10.1002/art.38949.Fleischmann RM, Damjanov NS, Kivitz AJ, et al. A randomized, double-blind, placebo-controlled, twelve-week,dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with activerheumatoid arthritis. Arthritis Rheumatol. 2015 Feb;67(2):334-43. doi: 10.1002/art.38949.Burmester GR, Kremer JM, Van den Bosch F, et al. Safetyand efficacy of upadacitinib in patients with rheumatoidarthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018 Jun 23;391(10139): 2503-2512. doi: 10.1016/S0140-6736(18)31115-2. Epub 2018 Jun 18.Burmester GR, Kremer JM, Van den Bosch F, et al. Safetyand efficacy of upadacitinib in patients with rheumatoidarthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018 Jun 23;391(10139): 2503-2512. doi: 10.1016/S0140-6736(18)31115-2. Epub 2018 Jun 18.Genovese MC, Fleischmann R, Combe B, et al. Safety andefficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs (SELECT-BEYOND): a double-blind,randomised controlled phase 3 trial. Lancet. 2018 Jun 23;391(10139):25132524. doi: 10.1016/S0140-6736(18)31116-4. Epub 2018 Jun 18.Genovese MC, Fleischmann R, Combe B, et al. Safety andefficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs (SELECT-BEYOND): a double-blind,randomised controlled phase 3 trial. Lancet. 2018 Jun 23;391(10139):25132524. doi: 10.1016/S0140-6736(18)31116-4. Epub 2018 Jun 18.Насонов ЕЛ, Лила АМ. Ингибиция интерлейкина 6 при иммуновоспалительных ревматических заболеваниях: достижения, перспективы и надежды. Научнопрактическая ревматология. 2017;55(6): 590-9. doi: 10.14412/1995-4484-2017-590-599Nasonov EL, Lila AM. Inhibition of interleukin 6 in immune inflammatory rheumatic diseases: achievements, prospects, and hopes. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2017; 55(6):590-9. (In Russ.). doi: 10.14412/1995-4484-2017-590-599Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety oftofacitinib for the treatment of rheumatoid arthritis up to8.5 years: integrated analysis of data from the globalclinical trials. Ann Rheum Dis. 2017 Jul; 76(7):1253-1262. doi: 10.1136/annrheumdis-2016-210457. Epub 2017 Jan 31.Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety oftofacitinib for the treatment of rheumatoid arthritis up to8.5 years: integrated analysis of data from the globalclinical trials. Ann Rheum Dis. 2017 Jul; 76(7):1253-1262. doi: 10.1136/annrheumdis-2016-210457. Epub 2017 Jan 31.Genovese MC, Smolen JS, Takeuchi T, et al. Safety profileof baricitinib for the treatment of rheumatoid arthritis up to 5.5 years: an updated integrated safety analysis. ACR/ARHP Annual Meeting. San Diego: 38 November 2017. Abstr. 511.Genovese MC, Smolen JS, Takeuchi T, et al. Safety profileof baricitinib for the treatment of rheumatoid arthritis up to 5.5 years: an updated integrated safety analysis. ACR/ARHP Annual Meeting. San Diego: 38 November 2017. Abstr. 511.Winthrop KL, Curtis JR, Lindsey S, et al. Herpes zoster andtofacitinib. Clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol. 2017 Oct;69(10):1960-1968. doi: 10.1002/art.40189. Epub 2017 Sep 6.Winthrop KL, Curtis JR, Lindsey S, et al. Herpes zoster andtofacitinib. Clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol. 2017 Oct;69(10):1960-1968. doi: 10.1002/art.40189. Epub 2017 Sep 6.Winthrop KL, Wouters AG, Choy EH, et al. The safety andimmunogenicity of live zoster vaccination in patients withrheumatoid arthritis before starting tofacitinib: a randomized phase II trial. Arthritis Rheumatol. 2017 Oct;69(10):1969-1977. doi: 10.1002/art.40187. Epub 2017 Sep 6.Winthrop KL, Wouters AG, Choy EH, et al. The safety andimmunogenicity of live zoster vaccination in patients withrheumatoid arthritis before starting tofacitinib: a randomized phase II trial. Arthritis Rheumatol. 2017 Oct;69(10):1969-1977. doi: 10.1002/art.40187. Epub 2017 Sep 6.Weinblatt M, Taylor PC, Burmester G, et al. Cardiovascularsafety during treatment with baricitinib in patients withrheumatoid arthritis. ACR/ARHP Annual Meeting. San Diego: 38 November 2017. Abstr. 499Weinblatt M, Taylor PC, Burmester G, et al. Cardiovascularsafety during treatment with baricitinib in patients withrheumatoid arthritis. ACR/ARHP Annual Meeting. San Diego: 38 November 2017. Abstr. 499Xie F, Yun H, Bernatsky S, Curtis JR. Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis Rheumatol. 2016 Nov;68(11):2612-2617. doi: 10.1002/art.39761.Xie F, Yun H, Bernatsky S, Curtis JR. Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis Rheumatol. 2016 Nov;68(11):2612-2617. doi: 10.1002/art.39761.Smolen JS, Genovese MC, Takeuchi T. Safety profile ofbaricitinib in patients with active rheumatoid arthritis: anintegrated analysis. European League Against Rheumatism (EULAR). London; 8–11 June 2016. Poster THU0166.Smolen JS, Genovese MC, Takeuchi T. Safety profile ofbaricitinib in patients with active rheumatoid arthritis: anintegrated analysis. European League Against Rheumatism (EULAR). London; 8–11 June 2016. Poster THU0166.Schulze-Koops H, Strand V, Nduaka C, et al. Analysis ofhaematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-termextension studies. Rheumatology (Oxford). 2017 Jan;56(1):46-57. doi: 10.1093/rheumatology/kew329. Epub 2016 Oct 22.Schulze-Koops H, Strand V, Nduaka C, et al. Analysis ofhaematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-termextension studies. Rheumatology (Oxford). 2017 Jan;56(1):46-57. doi: 10.1093/rheumatology/kew329. Epub 2016 Oct 22.Kremer JM, Checn L, Saifan CG, et al. Analysis of neutrophils, lymphocytes, and platelets in pooled phase 2 andphase 3 studies of baricitinib for rheumatoid arthritis. European League Against Rheumatism (EULAR). Madrid; 14–17 June 2017. Poster 1325.Kremer JM, Checn L, Saifan CG, et al. Analysis of neutrophils, lymphocytes, and platelets in pooled phase 2 andphase 3 studies of baricitinib for rheumatoid arthritis. European League Against Rheumatism (EULAR). Madrid; 14–17 June 2017. Poster 1325.Charles-Schoeman C, Gonzalez-Gay MA, Kaplan I, et al. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. Semin Arthritis Rheum. 2016 Aug;46(1): 71-80. doi: 10.1016/j.semarthrit.2016.03.004. Epub 2016 Mar 9.Charles-Schoeman C, Gonzalez-Gay MA, Kaplan I, et al. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. Semin Arthritis Rheum. 2016 Aug;46(1): 71-80. doi: 10.1016/j.semarthrit.2016.03.004. Epub 2016 Mar 9.Isaacs JD, Zuckerman A, Krishnaswami S, et al. Changesin serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials. Arthritis Res Ther. 2014 Jul 25;16(4):R158. doi: 10.1186/ar4673.Isaacs JD, Zuckerman A, Krishnaswami S, et al. Changesin serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials. Arthritis Res Ther. 2014 Jul 25;16(4):R158. doi: 10.1186/ar4673.McInnes IB, Kremer J, Emery P, et al. Lipid profile andeffect of statin treatment in pooled phase 2 and phase 3baricitinib studies. 2016 ACR/ARHP Annual Meeting. Abstract No. 3023.McInnes IB, Kremer J, Emery P, et al. Lipid profile andeffect of statin treatment in pooled phase 2 and phase 3baricitinib studies. 2016 ACR/ARHP Annual Meeting. Abstract No. 3023.

The authors declare that there are no conflicts of interest present.